Cargando…

Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers

Antimicrobial drug concentrations in the gastrointestinal tract likely drive antimicrobial resistance in enteric bacteria. Our objective was to determine the concentration of ceftiofur and its metabolites in the gastrointestinal tract of steers treated with ceftiofur crystalline-free acid (CCFA) or...

Descripción completa

Detalles Bibliográficos
Autores principales: Foster, Derek M., Jacob, Megan E., Farmer, Kyle A., Callahan, Benjamin J., Theriot, Casey M., Kathariou, Sophia, Cernicchiaro, Natalia, Prange, Timo, Papich, Mark G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777789/
https://www.ncbi.nlm.nih.gov/pubmed/31584976
http://dx.doi.org/10.1371/journal.pone.0223378
_version_ 1783456668367978496
author Foster, Derek M.
Jacob, Megan E.
Farmer, Kyle A.
Callahan, Benjamin J.
Theriot, Casey M.
Kathariou, Sophia
Cernicchiaro, Natalia
Prange, Timo
Papich, Mark G.
author_facet Foster, Derek M.
Jacob, Megan E.
Farmer, Kyle A.
Callahan, Benjamin J.
Theriot, Casey M.
Kathariou, Sophia
Cernicchiaro, Natalia
Prange, Timo
Papich, Mark G.
author_sort Foster, Derek M.
collection PubMed
description Antimicrobial drug concentrations in the gastrointestinal tract likely drive antimicrobial resistance in enteric bacteria. Our objective was to determine the concentration of ceftiofur and its metabolites in the gastrointestinal tract of steers treated with ceftiofur crystalline-free acid (CCFA) or ceftiofur hydrochloride (CHCL), determine the effect of these drugs on the minimum inhibitory concentration (MIC) of fecal Escherichia coli, and evaluate shifts in the microbiome. Steers were administered either a single dose (6.6 mg/kg) of CCFA or 2.2 mg/kg of CHCL every 24 hours for 3 days. Ceftiofur and its metabolites were measured in the plasma, interstitium, ileum and colon. The concentration and MIC of fecal E. coli and the fecal microbiota composition were assessed after treatment. The maximum concentration of ceftiofur was higher in all sampled locations of steers treated with CHCL. Measurable drug persisted longer in the intestine of CCFA-treated steers. There was a significant decrease in E. coli concentration (P = 0.002) within 24 hours that persisted for 2 weeks after CCFA treatment. In CHCL-treated steers, the mean MIC of ceftiofur in E. coli peaked at 48 hours (mean MIC = 20.45 ug/ml, 95% CI = 10.29–40.63 ug/ml), and in CCFA-treated steers, mean MIC peaked at 96 hours (mean MIC = 10.68 ug/ml, 95% CI = 5.47–20.85 ug/ml). Shifts in the microbiome of steers in both groups were due to reductions in Firmicutes and increases in Bacteroidetes. CCFA leads to prolonged, low intestinal drug concentrations, and is associated with decreased E. coli concentration, an increased MIC of ceftiofur in E. coli at specific time points, and shifts in the fecal microbiota. CHCL led to higher intestinal drug concentrations over a shorter duration. Effects on E. coli concentration and the microbiome were smaller in this group, but the increase in the MIC of ceftiofur in fecal E. coli was similar.
format Online
Article
Text
id pubmed-6777789
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-67777892019-10-13 Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers Foster, Derek M. Jacob, Megan E. Farmer, Kyle A. Callahan, Benjamin J. Theriot, Casey M. Kathariou, Sophia Cernicchiaro, Natalia Prange, Timo Papich, Mark G. PLoS One Research Article Antimicrobial drug concentrations in the gastrointestinal tract likely drive antimicrobial resistance in enteric bacteria. Our objective was to determine the concentration of ceftiofur and its metabolites in the gastrointestinal tract of steers treated with ceftiofur crystalline-free acid (CCFA) or ceftiofur hydrochloride (CHCL), determine the effect of these drugs on the minimum inhibitory concentration (MIC) of fecal Escherichia coli, and evaluate shifts in the microbiome. Steers were administered either a single dose (6.6 mg/kg) of CCFA or 2.2 mg/kg of CHCL every 24 hours for 3 days. Ceftiofur and its metabolites were measured in the plasma, interstitium, ileum and colon. The concentration and MIC of fecal E. coli and the fecal microbiota composition were assessed after treatment. The maximum concentration of ceftiofur was higher in all sampled locations of steers treated with CHCL. Measurable drug persisted longer in the intestine of CCFA-treated steers. There was a significant decrease in E. coli concentration (P = 0.002) within 24 hours that persisted for 2 weeks after CCFA treatment. In CHCL-treated steers, the mean MIC of ceftiofur in E. coli peaked at 48 hours (mean MIC = 20.45 ug/ml, 95% CI = 10.29–40.63 ug/ml), and in CCFA-treated steers, mean MIC peaked at 96 hours (mean MIC = 10.68 ug/ml, 95% CI = 5.47–20.85 ug/ml). Shifts in the microbiome of steers in both groups were due to reductions in Firmicutes and increases in Bacteroidetes. CCFA leads to prolonged, low intestinal drug concentrations, and is associated with decreased E. coli concentration, an increased MIC of ceftiofur in E. coli at specific time points, and shifts in the fecal microbiota. CHCL led to higher intestinal drug concentrations over a shorter duration. Effects on E. coli concentration and the microbiome were smaller in this group, but the increase in the MIC of ceftiofur in fecal E. coli was similar. Public Library of Science 2019-10-04 /pmc/articles/PMC6777789/ /pubmed/31584976 http://dx.doi.org/10.1371/journal.pone.0223378 Text en © 2019 Foster et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Foster, Derek M.
Jacob, Megan E.
Farmer, Kyle A.
Callahan, Benjamin J.
Theriot, Casey M.
Kathariou, Sophia
Cernicchiaro, Natalia
Prange, Timo
Papich, Mark G.
Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers
title Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers
title_full Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers
title_fullStr Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers
title_full_unstemmed Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers
title_short Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers
title_sort ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal escherichia coli, and the microbiome of steers
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777789/
https://www.ncbi.nlm.nih.gov/pubmed/31584976
http://dx.doi.org/10.1371/journal.pone.0223378
work_keys_str_mv AT fosterderekm ceftiofurformulationdifferentiallyaffectstheintestinaldrugconcentrationresistanceoffecalescherichiacoliandthemicrobiomeofsteers
AT jacobmegane ceftiofurformulationdifferentiallyaffectstheintestinaldrugconcentrationresistanceoffecalescherichiacoliandthemicrobiomeofsteers
AT farmerkylea ceftiofurformulationdifferentiallyaffectstheintestinaldrugconcentrationresistanceoffecalescherichiacoliandthemicrobiomeofsteers
AT callahanbenjaminj ceftiofurformulationdifferentiallyaffectstheintestinaldrugconcentrationresistanceoffecalescherichiacoliandthemicrobiomeofsteers
AT theriotcaseym ceftiofurformulationdifferentiallyaffectstheintestinaldrugconcentrationresistanceoffecalescherichiacoliandthemicrobiomeofsteers
AT kathariousophia ceftiofurformulationdifferentiallyaffectstheintestinaldrugconcentrationresistanceoffecalescherichiacoliandthemicrobiomeofsteers
AT cernicchiaronatalia ceftiofurformulationdifferentiallyaffectstheintestinaldrugconcentrationresistanceoffecalescherichiacoliandthemicrobiomeofsteers
AT prangetimo ceftiofurformulationdifferentiallyaffectstheintestinaldrugconcentrationresistanceoffecalescherichiacoliandthemicrobiomeofsteers
AT papichmarkg ceftiofurformulationdifferentiallyaffectstheintestinaldrugconcentrationresistanceoffecalescherichiacoliandthemicrobiomeofsteers